Diisopropylethylamine → HCID 86596951, compound
Reaction equation
[Cl:1][C:2]1[N:11]=[C:10](Cl)[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([Cl:13])[CH:8]=2)[N:3]=1.[NH2:14][CH2:15][C:16]([NH:18][C@H:19]1[CH2:24][CH2:23][C@@H:22]([N:25]([CH2:29][CH3:30])[CH:26]([CH3:28])[CH3:27])[CH2:21][C@H:20]1[CH2:31][O:32][CH3:33])=[O:17].C(N(C(C)C)CC)(C)C>O1CCCC1>[Cl:1][C:2]1[N:11]=[C:10]([NH:14][CH2:15][C:16]([NH:18][C@H:19]2[CH2:24][CH2:23][C@@H:22]([N:25]([CH2:29][CH3:30])[CH:26]([CH3:28])[CH3:27])[CH2:21][C@H:20]2[CH2:31][O:32][CH3:33])=[O:17])[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([Cl:13])[CH:8]=2)[N:3]=1Participants
5
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
A solution of 2,4,6-trichloroquinazoline (103 mg) and the bis-trifluoroacetic acid salt of 2-amino-N-((1S,2R,4R)-4-(ethyl(isopropyl)amino)-2-(methoxymethyl)cyclohexyl)acetamide (152 mg) in tetrahydrofuran (3 mL) was treated with diisopropylethylamine (0.31 mL) and the mixture was stirred overnight at rt. The mixture was concentrated and purified by reverse phase HPLC and lyophilization to provide the bis-trifluoroacetic acid salt of the title compound, 2-(2,6-dichloroquinazolin-4-ylamino)-N-((1S,2R,4R)-4-(ethyl(isopropyl)amino)-2-(methoxymethyl)cyclohexyl)acetamide, as a white powder (79 mg). MS found: (M+H)+=482.2.
Workup
- concentrationThe mixture was concentrated
- custompurified by reverse phase HPLC and lyophilization
Sources & evidence
- ORD record
- ord-784879a3cc7a459680430cdd132dde96
- Source dataset
- uspto-grants-2008_05
- Patent number
- US07378409B2
Reaction notes
Loading…